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Małgorzata Dudkiewicz,1 Piotr Malanowski,2 Jarosław Czerwin´ski,2 Krzysztof Pawłowski1,3In hematopoietic stem cell transplantation (HSCT), the outcome is predicted using HLA-matching proce-
dures, which are very time-consuming. There exists substantial evidence of the importance of early donor
acceptance in HSCToutcome. In cases when the donor cannot be perfectly matched, it often is unclear which
mismatch is less harmful and thus has a greater likelihood of acceptance. We modeled and analyzed interac-
tions between the protein products of different HLA alleles of the transplant recipient and natural killer and T
lymphocyte cell receptors of the donor’s immune system. Reactions between these 2 systems often lead to
graft-versus-host disease (GVHD). Sequence polymorphisms that define HLA I and II alleles predict not only
GVHD, but also host-versus-graft and graft-versus-leukemia effects, all of which influence the overall trans-
plantation outcome. Although complete high-resolution HLA matching of the donor–recipient pair seems to
be associated with optimal post-HSCT survival, recent reports suggest that not every HLA disparity is func-
tionally relevant. We performed interaction energy calculations for selected pairs of donor-recipient HLA
alleles. Based on the results, we conclude that the energy of contact between the T lymphocyte cell receptor
(TCR) and HLA residues can help predict the future development of an immune reaction and, consequently,
the outcome of allogeneic HSCT.
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T cells use T lymphocyte cell receptors (TCRs)
to recognize short antigenic peptides presented by class
I and class II major histocompatibility complex (MHC)
molecules expressed by antigen-presenting cells (APCs).
As suggested by numerous laboratory studies [1,2], the
potency of the ligand (presented peptide) to activate T
cells correlates with the half-life of the TCR–peptide
MHC (pMHC) complex [3,4] and likely also with
heat-capacity changes during the interaction [1]. The
binding affinity of TCRs to ligands also has been
reported to correlate with T cell response in vivo [5].1Department of Experimental Design and Bioinformatics,
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6/j.bbmt.2009.05.011The binding of TCR to its pMHC ligand is a low-
affinity interaction that depends very strongly on the
presented peptide. Identifying universal key residues
that can determine the effects of binding in all known
TCR–pMHC complexes is difficult; however, CDR1
and CDR2 loops of the TCR alpha and beta chains
are known to preferably contact MHC alpha helices
from the binding groove, and CDR3 loops are in-
volved in peptide binding. Thermodynamic studies
of TCR–pMHC interactions have shown that many
TCRs bind to pMHCs by an induced fit mechanism,
meaning that the binding surface is flexible and stabi-
lizes only on ligand engagement [6-9], whereas the
pMHC part of the complex is assumed to be relatively
rigid [10]. Numerous approaches for determining the
energy of the TCR–pMHC complexes in laboratory
conditions are available, most of them based on the as-
sumption that the loss of entropy in the system is con-
sistent with the stabilization of the binding site
produced by ligand binding. Experimental results
show a wide range of possible thermodynamic values
in the case of native complexes (from about -127.5
kJ/mol to 1.6 kJ/mol) [2,4]. In almost all TCR–
pMHC I complexes characterized so far, the pMHC
part is relatively rigid on TCR engagement. These
studies were conducted with TCR interactions
Table 1. Donor matching guidelines according to medical
practice [16,18,19]
U Always search for an optimal match (10/10) at the allele level in 5 loci
(HLA-A, -B, -C, -DR, and -DQ).
U Allele mismatch is less harmful than antigen mismatch.
U If a fully matched donor is not available, choose a one-mismatch donor
over a double-mismatch donor.
U Choose a donor with a mismatch in HLA-A over one with a mismatch in
HLA-B.
U Choose a mismatch with a lower number of amino acid substitutions
between alleles.
U If there are 2 one-mismatch donors with a single amino acid substitution
in the same locus, choose the donor with the substitution outside the
binding groove.
U Because GVHD may increase the risk of HSCT-related mortality, avoid
mismatches that could lead to GVHD.
Biol Blood Marrow Transplant 15:1014-1025, 2009 1015Bioinformatics Approach to Predicting HSCT Outcomeinvolving small peptides (8 to 9 residues long), how-
ever. Recently, it has been reported that peptides lon-
ger than 10 amino acids can bulge centrally from the
MHC binding groove and exhibit some degree of mo-
bility [11].
According to Shlomchik et al. [12], the crucial
point in graft-versus-host disease (GVHD) initiation
is presentation of the antigen by host APCs. It has
been shown experimentally that depleting host APCs
before the conditioning regimen for the donor T cell
transplantation into the murine hematopoietic stem
cell transplantation (HSCT) model abrogates
GVHD. These results suggest that replacement of
host APCs with donor cells reduces the likelihood
that donor CD81 T cells interacting with a host
APC will induce GVHD. Both class I and II participate
in the presentation of intracellular peptides to donor
T cell receptors, and both are expressed by APCs.
According to Petersdorf and coworkers [13,14], mis-
matching HLA class II increases the risk of acute
GVHD (aGVHD) more than mismatching HLA
class I.
One of the most critical first steps in HSCT is
ensuring that the donor and recipient are a good
match in terms of the 5 main transplant antigens:
HLA-A, -B, -C, -DR, and -DQ. This is of particular
concern for those receiving an allogeneic transplant,
which involves the donation of stem cells by a family
member, an unrelated individual, or a banked cord
blood unit.
HLA matching is a key factor in the overall success
of HSCT, as well as in preventing possible complica-
tions, such as GVHD or relapse. GVHD can be a ma-
jor complication after allogeneic HSCT, especially
when the donor and recipient are unrelated. Activated
donor cytotoxic T lymphocytes (CTLs) and natural
killer cells (NKCs) produce granzymes (Gr) that are
involved in the pathogenesis of GVHD. In contrast,
activated donor T cells can eliminate leukemic host
cells and facilitate engraftment. All 3 of these factors
influence the general HSCT outcome, which is deter-
mined by patient survival after allogeneic HSCT [15].
The minimum acceptable match for a donor–re-
cipient pair initially was defined by matching at the se-
rologic level at 3 loci (HLA-A, -B, and -DR). Over the
years, however, the required level of typing resolution
has evolved to the present state, in which all 10Table 2. PDB structures and tested allele sequences
PDB ID MHC Peptide
2NX5 B*3501 EPLPQGQLTAY
2NW3 B*3508 EPLPQGQLTAY
1MI5 B*0801 FLRGRAYGL
PDB indicates Protein Data Bank; TCR, T lymphocyte cell receptor.antigens considered are determined at the genetic al-
lele level. Flomberg et al. [16] investigated the statisti-
cal associations between survival and mismatches, both
allele-level and serologic-level, and found that
serologic-level mismatches at MHC class I and
HLA-DR had a significant effect on survival. Accord-
ing to the analysis of Lee et al. [17], using data on 3857
transplantations performed between 1988 and 2003 in
the United States, a single mismatch detected by low-
or high-resolution DNA testing at HLA-A, -B, -C, or
-DRB1 was associated with higher mortality and lower
1-year survival rates compared with a perfect match.
Double mismatches were correlated with even higher
risk, whereas single mismatches at HLA-DQB1 or
-DP and donor factors other than HLA were not asso-
ciated with survival [17]. Considering these results, the
US National Marrow Donor Program has suggested
that a single allele-level donor–recipient mismatch is
preferable to an antigen-level donor–recipient mis-
match [18]. This rule remains in force in clinical prac-
tice. There are still no data allowing for the
discrimination of the effects of different mismatches
within the same serologic group. Table 1 summarizes
the operational rules and guidelines currently in place
at state-of-the-art medical practices.
As an alternative to the typical statistical studies of
post-HSCT survival and its correlation with donor–
recipient matching level, an approach involving
protein structural data has been proposed. In 2001,
Ferrara et al. [20] reported that mismatches with sub-
stitutions at the specific positions in the amino acid se-
quences of the HLA class I heavy chain can strongly
influence the outcome of bone marrow transplantationPeptide length, aa TCR Alleles tested
11 ELS4 B*3503 B*2702
B*2705 B*3508
11 —
9 LC13 B*3503 B*2702
B*2705 B*3508
Table 3. Summary of HSCT data (A), diagnoses and age distributions (B), and comparison of overall post-HSCT survival in 2
analyzed groups of patients (C)
(A)
Full Match
P Value for Difference
Between the Proportions Mismatch
IHWG data
Number of transplantations 628 410
Deceased 270 (42.9%) 0 366 (89.27%)
GVHD occurrences Not applicable Not applicable
GVHD as cause of death Not applicable Not applicable
Polish data
Number of transplantations 461 258
Deceased 165 (35.8%) .0067 119 (46.1%)
GVHD occurrences 60 .0155 51
GVHD as cause of death 35 (58.3%) .1786 36 (70.6%)
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HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-versus-host disease.
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cated a crucial role of the differences in amino acid po-
sition 116 of the HLA class I heavy chain. That study
was the first attempt to explain the effects of HLA mis-
match using structural data on MHC proteins. An-
other approach, presented by Petersdorf et al. [21],
suggests that typing of the 5 HLA loci is only a surro-
gate for haplotype matching between the donor and
recipient, which is of critical importance to HSCToutcome. Haplotype is defined by a series of markers
(both known and undetected HLA alleles) that may
be involved in the mediation of GVHD, GVL, and en-
graftment processes. Apart from HLA factors, many
non-MHC signals, including interleukins and cyto-
kines, play important roles in the second phase of
graft-versus-host (GVH) reaction development, parti-
cularly with respect to the proliferation and expansion
of T cells.
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Figure 1. Survival curves for patients with GVHD (gray) and without
GVHD (black) receiving transplants from unrelated donors with 2 kinds
of HLA-B mismatch, B*2702/2705 and B*3501/3503.
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Figure 2. Comparison of survival probability for patients from groups
distinguished on the basis of donor matching level: Lr match, low-reso-
lution match (allele mismatch); Lr MM, low-resolution mismatch (anti-
gen mismatch); DBMM, double mismatch (in 2 loci); FM, full-match–
high-resolution match.
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Our analysis was based on 3 x-ray structures from
Protein Data Bank (PDB) sources: 2NX5, 1MI5, and
2NW3 [11,22] (Table 2). The 3-dimensional structural
models of B*2702, B*2705, and B*3503 HLA class I al-
leles were constructed using Swiss-PdbViewer software
and the SWISS-MODEL automated homology model-
ing server (Swiss Institute of Bioinformatics, Basel, Swit-
zerland), at the amino acid sequences of these alleles,
available at the National Center for Biotechnology In-
formation’s dbMHC database. Different conformations
of presented peptides, all candidates for docking studies,
were obtained using the large-scale low-mode
(LLMOD) algorithm of MacroModel version 9.5
(Schro¨dinger, New York, NY) and original structures
of peptides bound to MHC in PDB structures 2NX5
(an 11-residue peptide of the BZLF antigen of Ep-
stein-Barr virus [EBV], designated EPLP) and 1MI5 (a
9-residue antigen of EBV). As proven experimentally
by in vitro lymphocyte cytotoxicity testing [11], HLA-
B*3501 elicits a strong immune response against the
EPLP determinant, but B*3508 does not elicit a notice-
able response to EPLP, even though HLA-B*3508 can
bind to EPLP, and the only difference between these 2
alleles is the single residue polymorphism Arg256
(B*3508)-Leu256 (B*3501). This was an important find-
ing on which to base further analysis.
To analyze our results and verify the matching
guidelines presented in Table 1, we collected data on
donor matching level and post-HST survival in 1757
cases (Table 3). We used the published data of the
HSCT component of the International Histocompat-
ibility Working Group (IHWG) (available at http://
www.ncbi.nlm.nih.gov/gv/mhc/ihwg), as well as data
collected by the Central Polish Bone Marrow Donor &
Cord Blood Registry, which contains data from more
than 700 HSCTs performed at Polish transplantationcenters between 2001 and 2008. Table 3 summarizes
these data and patient group descriptors.METHODS
We began by performing a statistical analysis of the
HLA data and post-HSCT survival data collected by
the Polish Central Bone Marrow Donor Registry and
the IHWG. This analysis allowed us to identify the
most frequent HLA mismatches between unrelated do-
nors and recipients. For selected groups, we performed
a Kaplan-Meier survival analysis, then compared
survival curves for different groups using the log-rank
test, in which the result for a given observation is calcu-
lated as a logarithm of survival function [17,23]. For the
IHWG data, no details about the cause of death or
GVHD were available.
Figure 1 shows plots comparing the survival rate
between the group of Polish patients diagnosed with
GVHD and patients without GVHD symptoms.
The influence of serologic-level and allele-level
mismatches on overall post-HSCT survival in the en-
tire cohort studied can be estimated using the data
given in Figure 2. We categorized the observed mis-
matches according to the mismatch type and level.
The most common B mismatch in our data set was
B*3501(recipient)/B*3503(donor); the second most
common was in donor–recipient pairs with B*2702/
B*2705 incompatibilities.
To investigate the influence of such mismatches on
the stability of the TCR–pMHC complex, we con-
structed a 3-dimensional structural model for each of
the 4 aforementioned HLA*B alleles. We generated
1018 Biol Blood Marrow Transplant 15:1014-1025, 2009M. Dudkiewicz et al.candidate peptide structures for docking using an
LLMOD conformational searching routine of
MacroModel 9.5 with constraints (Figure 3). The con-
formations obtained (. 800) were ranked according to
the energy and root mean square deviation (RMSD) of
alpha carbons from the original peptide conformations.
Subsequently, the 75 conformations with the lowest
values of energy and the 75 conformations with the
lowest RMSD were selected for further analysis.
TCR–peptide and TCR–MHC contact energies were
calculated using the MacroModel 9.5 multiple minimiza-
tion routine (force field: OPLS 2001; conjugate gradient
minimization method; convergence threshold: 1.0).
In the first step of the analysis, the structure of the
whole complex of peptide, MHC, and TCR was min-
imized. In the second step, the energy of the TCR–Figure 3. A, Structure substitution scheme: several candidate conformations o
MHC B*3501 ribbon representation (2) and the HLA-B alleles listed in Table 3
tation were considered during contact energy calculations. Red, presented peMHC contact zone (MHC residues within 5 A˚ of the
TCR and TCR residues within 5 A˚ of the HLA anti-
gen) was calculated in the OPLS 2001 force field.
The third step used the following energy subtrac-
tion formula:
Etotal5EMHC1ETCR1ETCR2MHC
Etotal2ETCR2EMHC5ETCR2MHC
(1)
Current energies for whole TCR and pMHC
parts of the complex were calculated as well. Then
we obtained TCR-MHC and TCR-p contact energies
by subtraction according to
Etotal5EMHC1ETCR1Ep1EMHC2p1ETCR2MHC1ETCR2p
Etotal2ETCR2EMHC2p2Ep2EMHC5ETCR2MHC1ETCR2p
(2)f EBV peptide–ball-and-stick representation (1) presented by the original
. B, TCR–MHC contact region. Residues in the ball-and-stick represen-
ptide; yellow, MHC; blue, TCR.
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Figure 4. Results of energy minimization for constructed TCR–pMHC
complexes for the 5 alleles evaluated. The y-axis represents the calcu-
lated energy of TCR–MHC contacts and TCR–-peptide contacts,
according to formula (1). The NX5 structure was used as a template.
2702, 2705, 3501 and 3503 are TCR–pMHC complex models discussed
in the text. 3508-ELS is a TCR–pMHC complex (B*3508/EBVp) that
does not activate T cells. 3508-NX5pep is a TCR–pMHC complex
(B*3508/EBVp) with peptide presented in conformation specific for
B*3501. X5ORG is a TCR–pMHC complex (B*3501/EBVp) triggering
T cell reaction.
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Figure 5. Contact energies for the 5 A˚ zone without ligand and with
only TCR and MHC residues, according to formula (2). Complexes
were reconstructed on the template of the 1NX5.pdb file.
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(EBV peptides from experimentally resolved human
pMHC/TCR structures). We did not analyze different
peptides in the context of the same MHC–TCR pair,
because the change of many factors at the same time
in such a complicated system could make the interpre-
tation of results obtained much more difficult or even
impossible. In this article, we discuss only some of the
results we obtained, focusing on the HLA-B mismatch
because it represents the greatest number of mis-
matched donor–recipient pairs, and because of the ev-
ident difference between patient survival curves. We
attempted to investigate DRB1 and DQB1 mis-
matches, but, in the case of HLA-DR, the number of
donor–recipient pairs with the same kind of allelic
difference was insufficient to perform statistical analysis.
In the case of HLA-DQ mismatch, we did not find
a statistically significant influence of this type of
donor–recipient difference on post-HSCT survival.
We obtained promising results from analyzing HLA-Table 4. Comparison of interaction energy differences calculated a
survival time observed in 2 groups of graft recipients with B*2702/2
Allele Pair DE (1)
t-Test P Value
for DE DE (2)
B*3503/B*3501 47.61 .067 1500.75
B*2705/B*2702 760.38 0 264.45
B*3501/B*3508 620.02 581.64C mismatches and HLA-Cp–KIR (killer cell immuno-
globulin-like receptor) complexes, but the specificity
of KIRs as receptors for APCs and their exceptional
role in the immune system makes this a subject for
separate analysis.RESULTS AND DISCUSSION
We replaced the HLA allele in the selected TCR–
pMHC complexes (based on the X-ray structures
deposited in the PDB database) to evaluate the influ-
ence of its substitution on the total energy of the im-
munologic synapse. We noted that the conformation
of the presented peptide is one of the most significant
factors determining the estimated recognition energy.
A second important observation is the dependence
of the calculated TCR–MHC and TCR–peptide inter-
action energy on the number and localization of amino
acid substitutions between alleles. The difference in
contact energy between alleles with a higher number
of substitutions (eg, B*2702/2705, B*3501/3508) or be-
tween separate HLA-B groups (eg, B27/B35) exceeds
the differences between tested complexes containing
similar alleles varying at a single amino acid position
(eg, B*3501/3503) (Figure 4 and Table 4). This rule re-
mains valid for a second analyzed structure, 1MI5, inccording to formulas (1) and (2) for 3 pairs of alleles and mean
705 mismatches and B*3501/3503 mismatches
t-Test P Value
for DE
Mean Survival,
Days
P Value
for Survival Curve
Difference (Log-Rank Test)
0 361.7 .01224
0 1102.2
No data
Figure 6. The molecular surface of the TCR–MHC contact zone with
the presented EBV peptide depicted using a ball-and-stick model. TCR
chain A, orange; chain B, blue; HLA chain A, grey
1020 Biol Blood Marrow Transplant 15:1014-1025, 2009M. Dudkiewicz et al.which the original HLA belongs to a different HLA-B
group (B*0801). Comparing the interaction energy cal-
culated for a complex that does not activate T cells in
vivo (PDB code 2NW3 [11]) with energies obtained
through substitution of B*3501 by B*2705 and
B*2702, we can conclude that the latter complexes
should not trigger a TCR ELS4 reaction. This can pro-
vide insight into the possible consequences of B*2702 or
B*2705/B*3501 mismatches.
Our analysis of TCR–MHC interactions alone
demonstrated quite different relationships betweenFigure 7. Residues of MHC class I making contact on TCR (sorted by MHC
(according to Rudolph et al. [9]) and a proximity parameter of 5 A˚. SNP B*35
The following MHC residues made the most contacts on TCR residues: A58,
A 147, A149, A150, A151, A152, A154, A 155, A158, A159, A162, A163, A16the same alleles, however (Figure 5). The differences
in the interaction energies calculated for B*3501 and
B*3503 were much higher than those calculated for
B*2702 and B*2705, despite the greater number of
overall amino acid differences between the alleles
from the second pair. There were no differences
between B*3501 and B*3503 in the contact zone, as
defined based on molecular distances and literature
data (Figures 6 and 7). The only amino acid substitu-
tion between B*3501 and B*3503 was located in the
a-helix of a binding groove, quite far from the contact
surface of the antigen (Figures 7 and 8). Perhaps sub-
stitutions localized in the binding groove can influence
TCR–MHC energy indirectly.
After measuring the interaction energies for the
TCR–MHC and TCR–peptide interactions, we at-
tempted to relate them to HSCT outcomes. We chose
the 2 most numerous groups of donor–recipient pairs
from the database. In the first group, the only donor–re-
cipient difference was the HLAB*3501–HLAB*3503
mismatch; in the second group, the mismatch involved
HLAB*2702 and HLAB*2705.
We decided to consider post-HSCT survival time as
a measure of transplantation success, because we did not
have sufficient data on GVHD occurrence in the 2 pa-
tient groups. Figure 9 compares the survival curves ob-
tained for the 2 groups selected from all available data.
We observed that preliminarily, the patients under-
going transplantation with B*2702/2705 mismatchesresidues) based on the known structures of TCR–pMHC complexes
01/3503 and B*27-2/2705 also are shown (A105, 104, 101, and A141).
A59, A62, A65, A66, A69, A69, A70, A72, A73, A75, A76, A79, A146,
6, A167, and A170.
Figure 8. Aligned sequences of 4 analyzed alleles of HLA-B. A, Amino acid differences between alleles of the same group (B2702-B2705 [black] and
B3501-B3503 [blue]). B, Amino acid differences between alleles belonging to the separate HLA groups (B27 vs B35).
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Figure 9. Comparison of survival curves for 2 groups of HSCT recip-
ients who received transplants from B*3501/3503 mismatched donors
(MM 3501/3503; dotted line) and from B*2702/2705 mismatched do-
nors (MM 2702/2705; solid line) (n 5 18).
Table 5. Comparison of the relationship between donor–
recipientHLAmatching level[A,mismatched, full-matched,and
double-mismatched pairs; B, low-resolution matches and low-
resolution mismatches] and causes of post-HSCTmortality
(A) FM MM P
Deceased 166 116
Alive 293 143
Cause of death
GVHD 38 (36%) 36 (46%) .16923
Graft rejection/relapse 32 (30%) 17 (22%) .222273
Infection 19 (21%) 11 (16%) .389036
Organ failure 10 (9%) 6 (8%) .809733
Other 8 (7%) 9 (11%) .338648
Total 107 79
No data available 59 (36%) 37 (32%)
(B) LrMM LrMatch P
Deceased 69 29
Alive 82 38
Cause of death
GVHD 20 (44%) 9 (41%) .815817
Graft rejection/relapse 8 (18%) 7 (32%) .198171
Infection 7 (16%) 3 (14%) .831077
Organ failure 5 (11%) 0
Other 5 (11%) 3 (14%) .72254
Total 45 22
No data available 24 (35%) 7 (24%)
HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-
versus-host disease.
Table 6. Affect of the type of donor–recipient mismatch of
GVHD occurrence
Mismatch MHC Class I MHC Class II DBMM FM
Number of patients 181 47 32 461
Percentage of patients with
GVHD symptoms
22% 11% 19% 13%
P value of binomial
proportion
difference test (between a
given mismatch group and
the FM control group)
.004621 .695966 .335145 –
GVHD indicates graft-versus-host disease; FM, full match, high resolu-
tion match.
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B*3501/3503 mismatches; however, this observation
needs to be confirmed using a larger sample size. Our
results should be considered preliminary because of
the modest sample size, but nonetheless, the difference
in survival is striking. Inferring cause-and-effect rela-
tionships using clinical data often is difficult because
of the many factors that can possibly influence a medical
outcome. TCR–MHC interaction and binding is the
first step in pMHC complex recognition and has
a potentially far-reaching influence on the later stages
of the immune response and, consequently, on post-
HSCT survival. When the TCR–MHC interaction
energy is too low, the TCR may not be engaged. If
this occurs, then an immune reaction is not triggered,
making the patient susceptible to infections, a major
cause of death in post-HSCT patients.
When the TCR recognizes an MHC molecule, the
initial complex aggregates, and the TCR has an oppor-
tunity to interact with the presented peptide. The
results of recognition and T cell activation then
depend on the origin of the presented antigen. If the
antigen is host-derived, then T cell activation leads
to development of GVHD symptoms. But, if the rec-
ognized peptide originates from a pathogen, then the
immune response thus initiated is beneficial to the
host organism. If the TCR–p interaction energy is
too low to trigger T cell activation, immunodeficiency
can result. Thus, we assume that the observed post-
HSCT mortality caused by GVHD and infections
can be influenced by initial interactions between
TCRs and MHC molecules.
We also attempted to analyze in detail a possible
relationship between the cause of death and the type
of donor–recipient mismatch. The results, presented
in Table 5, show that the differences in fractionsbetween distinguished groups were not statistically
significant. According to the data, higher GVHD
risk was associated with MHC class I mismatch, but
not with MHC class II mismatch (Table 6), just the
opposite of what has been reported previously
[13,24]. This discrepancy possibly could result from
the fact that in our cohort, causes of donor–recipient
mismatch at HLA-DRB1 were very poorly repre-
sented (presumably as a consequence of the matching
rule to ‘‘avoid class II mismatches’’).
Our data do not support the assumption that
mismatches with overall fewer substitutions (when mis-
matched alleles belong to the same HLA serologic
group) are less harmful. The survival for B*3501/3503
donor–recipient pairs (1 Single Nucleotide Polymor-
phism [SNP]) is worse than that for B*2702/2705
(3 SNPs) mismatched group. This may result from the
fact that, in the former case, the SNP occurs in the
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Figure 10. Comparison of survival probability for patients from groups distinguished on the basis of the mismatched HLA locus: MMA, patients re-
ceiving transplants from HLA-A–mismatched donors; FM, patients receiving transplants from fully matched donors; DBMM, patients receiving trans-
plants from donors mismatched at more than 1 locus. A, Curves plotted based on the whole data set. B, Curves plotted based on only the IHWG
data. C, Curves plotted for only the Polish patients.
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B*2702 and B*2705 are found outside of the antigen-
presenting region.
To verify the remaining general guidelines for donor
matching, we analyzed the full data set in terms of the dif-
ferent types and levels of donor–recipient mismatches.
The first rule, ‘‘always search for an optimal match’’
[19], seems justified based on the survival curves (Figures
2, 10, and 11); the difference between the survival curve
for patients who received transplants from fully matched
donors and the curve for patients with suboptimal matches
is statistically significant at a confidence level of 99% (P5
.00017). The statement to the effect that allele mismatch is
more often accepted and less harmful than antigen mis-
match remains unconfirmed, however (P5 .93).
The recommendation to choose a donor with a mis-
match in HLA-A rather than in HLA-B seems invalid.
The survival curve for patients receiving transplantsfrom HLA-A–mismatched donors is worse than that
for those receiving transplants from HLA-B–
mismatched donors (Figure 10A and B). This difference
is statistically significant (P 5 .00161). A separate anal-
ysis of the data set from Polish transplantation centers
does not confirm this rule, however (Figure 10C). It is
possible that survival in recipients of mismatched grafts
depends on many other factors associated with clinical
conditions and treatment policies.
The conjecture that GVHD may increase the risk
of poor HSCT outcomes, and thus mismatches that
possibly could cause GVHD should be avoided, could
be verified based only on the Polish data set, because
there was no appropriate annotation in the IHWG
files. A diagnosis of GVHD strongly influenced the
overall survival (OS) of the Polish HSCT recipients;
the survival probability of recipients with GVHD
symptoms was half that of recipients without GVHD.
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Figure 11. Survival curves for patients receiving transplants from do-
nors mismatched in MHC class I or class II and for the fully matched con-
trol group.
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MHC interaction energies [formula (2)] in the first
step of the TCR recognition of the MHC-p complex
can aid the prediction of the final immune response
and thus the survival of HSCT recipients. Small differ-
ences between the estimated energies of interaction
(EMHC-TCR 1 ETCR-p) between the donor TCR and
MHC compared with the recipient TCR and MHC
seem to correlate with better survival. Furthermore,
the difference in binding energy between HLA alleles
is not directly related to the number of amino acid
substitutions between them. Even substitutions in
residues distant from the contact zone can change
the TCR–MHC surface binding energy, particularly
if the substitution occurs in the peptide-binding
groove. Contact energy differences between alleles
belonging to the same serologic group of HLA-B are
not always smaller than the difference values calculated
for alleles from different antigen groups.
Verification of the relationships proposed herein
requires further study and analysis of more HLA
loci. The lack of appropriate data is a significant limi-
tation, because transplantation from mismatched, un-
related donors is generally a last resort, making it
difficult to collect a sample of adequate size. HSCT
is a relatively new medical procedure, and despite the
many international projects and studies conducted to
date, many unexplained phenomena related to this
procedure remain.ACKNOWLEDGMENTS
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